ClinicalTrials.gg
CompletedNCT00727961Updated Jun 8, 2017Results posted

A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED)

A Phase 4 interventional study of Pegylated Liposomal Doxorubicin hydrochloride in Ovarian Neoplasms, sponsored by Merck Sharp & Dohme LLC. Completed. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-08.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 7 months after the study started (first participant enrolled Nov 2004, registered Jun 2008).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
58
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies testing liposomal doxorubicin in Ovarian Neoplasms — none open to participants now, 3 under way, 2 of them phase 3. liposomal doxorubicin · Ovarian Neoplasms.

Enrollment
18th of 42
58 · median 53
Started
2004
the only one that year
Phase 4
Only one
of the 42
Registered
10th of 42
by date

Among the 42 studies testing liposomal doxorubicin in Ovarian Neoplasms, this one is the 18th largest by enrollment, is the only one that started in 2004, is the only one in phase 4, and was the 10th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

None of the 42 studies testing liposomal doxorubicin in Ovarian Neoplasms is open now. The open studies under Ovarian Neoplasms, anywhere →

About liposomal doxorubicin

liposomal doxorubicin: first FDA approval 1995 (DOXIL (LIPOSOMAL)), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 42 studies testing liposomal doxorubicin in Ovarian Neoplasms as a file.
02

Study summary

The aim of this study is to evaluate efficacy and tolerability, and number of positive response to treatment with CAELYX (50 mg/m\^2), administered as monotherapy once per 4 weeks to patients with metastatic epithelial ovarian cancer, resistant to previous platinum therapy.

03

Conditions studied

  • Ovarian Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must demonstrate their willingness to participate in the study and comply with its procedures by signing a written and/or parent or legal guardian must have signed a written informed consent.
  • Women must be greater than or equal to 18 years of age, of any race.
  • Women of (includes women who are less than 1 year and women who become sexually active) must be using an acceptable method of (e.g., hormonal contraceptive, medically prescribed IUD, condom in combination with spermicide) or be surgically sterilized (e.g., hysterectomy or tubal ligation).
  • Morphology (cytology or histology) confirmed diagnosis of epithelial ovarian cancer.
  • Patients with 1 or more measurable and/or evaluable tumors, according to the results of CT, MRT scans or X-ray, etc.
  • Patients, including those after primary surgical treatment, who had previously received platinum chemotherapy and in whom therapy is indicated.
  • performance status above 60%.
  • above 50% (according to the results of echocardiography).
  • Adequate bone marrow function as indicated by:

    • >100x10\^9/L
    • > 9 g/dL
    • >1.5x10\^9/L
  • Adequate renal function as indicated by:

    • Serum creatinine \< 1.5 х
  • Adequate liver function as indicated by:

    • level and or ALT activity \< 2 х ULN (with the exception of cases related to primary disease).

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or nursing.
  • Subjects who have not observed the designated for any of the prohibited medications.
  • Subjects who have used any product within 30 days prior to enrollment.
  • Medical history indicating serious concomitant diseases, such as congestive heart failure of II class or higher, insulin-dependent diabetes mellitus, liver disease, mental disorders.
  • Non-controlled bacterial, viral or fungal infections.
  • Conditions and reasons (medical, social and psychological) that might prevent adequate follow-up of patients.
  • Any other active primary tumor under treatment (except basal or squamous cell carcinoma or in situ cervix carcinoma).
  • Patient has symptomatic to brain.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    Arm 1

    Caelyx Intravenous, 50 mg/m\^2, given for 6 cycles

    Drug: Pegylated Liposomal Doxorubicin hydrochloride

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Complete Response

    Complete response was defined as complete disappearance of all measurable and assessable disease with no new disease or disease-related symptoms as measured by chest x-ray, computed tomography scan, and magnetic resonance imaging.

    Time frame: 4 weeks after chemotherapy completed

  2. Number of Participants With Partial Response

    Required 50 percent or greater decrease in sum of products of all bidimensionally measurable lesions without progression of assessable disease and no new lesions as measured by chest x-ray, computed tomography scan, and magnetic resonance imaging.

    Time frame: 4 weeks after chemotherapy completed

  3. Number of Participants With Stabilization

    All other subjects (except complete or partial responders and those with progression \[see prior definitions\]) were classified as stable disease as measured by chest x-ray, computed tomography scan, and magnetic resonance imaging.

    Time frame: 4 weeks after chemotherapy completed

  4. Number of Participants With Progression

    Progressive disease was defined as 25% or greater increase in the size of measurable lesion. The reappearance of any lesion or clear worsening of assessable disease or the appearance of any new lesion was also considered as progressive disease as measured by chest x-ray, computed tomography scan, and magnetic resonance imaging.

    Time frame: 4 weeks after chemotherapy completed

Secondary outcomes

  1. Mean Time to Positive (Partial) Treatment Response Achievement

    Time to the occurence of partial effect achievement as measured by chest x-ray, computed tomography scan, and magnetic resonance imaging. Partial response required a 50 percent or greater decrease in the sum of the products of all bidimensionally measurable lesions without progression of any assessable disease and no new lesions.

    Time frame: from the beginning of study drug administration up to 4 weeks after chemotherapy completed

  2. Median Time to Progression

    Median time to the occurence of progression. Progression was defined as 25 percent or greater increase size of measurable lesion. Reappearance of lesion, worsening of assessable disease or appearance new lesions were considered progression as measured by chest x-ray, computed tomography scan, and magnetic resonance imaging.

    Time frame: from the beginning of study drug administration up to 4 weeks after chemotherapy completed

  3. Mean Survival Time During the Study

    Mean time to the occurrence of death

    Time frame: from the beginning of study drug administration up to 18 months

07

Results

Posted Jul 16, 2009

Participant flow

Participant flow — Overall Study
MilestoneCaelyx Intravenous
Started58
Completed21
Not completed37
Withdrew: Lost to follow-up1
Withdrew: Adverse event4
Withdrew: Patient's refusal2
Withdrew: Progression30

Outcome measures

PrimaryNumber of Participants With Complete Response

Complete response was defined as complete disappearance of all measurable and assessable disease with no new disease or disease-related symptoms as measured by chest x-ray, computed tomography scan, and magnetic resonance imaging.

Time frame:
4 weeks after chemotherapy completed
Reported as:
Number · participants
Number of Participants With Complete Response
participantsCaelyx Intravenous
Number of Participants With Complete Response0
SecondaryMean Time to Positive (Partial) Treatment Response Achievement

Time to the occurence of partial effect achievement as measured by chest x-ray, computed tomography scan, and magnetic resonance imaging. Partial response required a 50 percent or greater decrease in the sum of the products of all bidimensionally measurable lesions without progression of any assessable disease and no new lesions.

Time frame:
from the beginning of study drug administration up to 4 weeks after chemotherapy completed
Reported as:
Mean · days
Mean Time to Positive (Partial) Treatment Response Achievement
daysCaelyx Intravenous
Mean Time to Positive (Partial) Treatment Response Achievement128.0000 ± 50.26430
SecondaryMedian Time to Progression

Median time to the occurence of progression. Progression was defined as 25 percent or greater increase size of measurable lesion. Reappearance of lesion, worsening of assessable disease or appearance new lesions were considered progression as measured by chest x-ray, computed tomography scan, and magnetic resonance imaging.

Time frame:
from the beginning of study drug administration up to 4 weeks after chemotherapy completed
Reported as:
Median · days
Median Time to Progression
daysCaelyx Intravenous
Median Time to Progression98.0 (88.8 to 107.2)
SecondaryMean Survival Time During the Study

Mean time to the occurrence of death

Time frame:
from the beginning of study drug administration up to 18 months
Reported as:
Mean · days
Mean Survival Time During the Study
daysCaelyx Intravenous
Mean Survival Time During the Study346.0 (272.3 to 419.7)
PrimaryNumber of Participants With Partial Response

Required 50 percent or greater decrease in sum of products of all bidimensionally measurable lesions without progression of assessable disease and no new lesions as measured by chest x-ray, computed tomography scan, and magnetic resonance imaging.

Time frame:
4 weeks after chemotherapy completed
Reported as:
Number · Participants
Number of Participants With Partial Response
ParticipantsCaelyx Intravenous
Number of Participants With Partial Response5
PrimaryNumber of Participants With Stabilization

All other subjects (except complete or partial responders and those with progression \[see prior definitions\]) were classified as stable disease as measured by chest x-ray, computed tomography scan, and magnetic resonance imaging.

Time frame:
4 weeks after chemotherapy completed
Reported as:
Number · Participants
Number of Participants With Stabilization
ParticipantsCaelyx Intravenous
Number of Participants With Stabilization10
PrimaryNumber of Participants With Progression

Progressive disease was defined as 25% or greater increase in the size of measurable lesion. The reappearance of any lesion or clear worsening of assessable disease or the appearance of any new lesion was also considered as progressive disease as measured by chest x-ray, computed tomography scan, and magnetic resonance imaging.

Time frame:
4 weeks after chemotherapy completed
Reported as:
Number · Participants
Number of Participants With Progression
ParticipantsCaelyx Intravenous
Number of Participants With Progression6

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Caelyx Intravenous—8/58 (13.8%)47/58 (81%)
Most frequent serious events
Most frequent serious events
EventCaelyx Intravenous
ALLERGIC TRANSFUSION REACTIONInjury, poisoning and procedural complications3/58
NEUTROPENIABlood and lymphatic system disorders1/58
PNEUMONIAInfections and infestations1/58
BRONCHOSPASMRespiratory, thoracic and mediastinal disorders1/58
DYSPNOEARespiratory, thoracic and mediastinal disorders1/58
VENOUS THROMBOSISVascular disorders1/58
Most frequent other events
Showing 10 of 19
Most frequent other events
EventCaelyx Intravenous
STOMATITISGastrointestinal disorders34/58
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROMESkin and subcutaneous tissue disorders33/58
FATIGUEGeneral disorders27/58
NEUTROPENIABlood and lymphatic system disorders15/58
NAUSEAGastrointestinal disorders13/58
RASHSkin and subcutaneous tissue disorders13/58
DIARRHOEAGastrointestinal disorders11/58
DRY SKINSkin and subcutaneous tissue disorders6/58
BODY TEMPERATURE INCREASEDInvestigations5/58
ANAEMIABlood and lymphatic system disorders4/58

Baseline characteristics

Age, Customized
Age, Customized(participants)Caelyx Intravenous
Number58
Sex: Female, Male
Sex: Female, Male(Participants)Caelyx Intravenous
Female58
Male0
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2004 to primary completion in Jan 2008, 38 months.

Results were first posted in Jul 2009, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2008
First posted
Aug 5, 2008
StartActual
Nov 9, 2004
Primary completionActual
Jan 10, 2008
CompletionActual
Jan 10, 2008
Results first posted
Jul 16, 2009
Last update
Jun 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00727961
Responsible party
Sponsor
First posted
Aug 5, 2008
Start date
Nov 9, 2004
Primary completion
Jan 10, 2008
Completion
Jan 10, 2008
Results posted
Jul 16, 2009
Last update
Jun 8, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal doxorubicin

Start the discussion